Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
- Épisodes
- 305
- Parution
- hebdomadaire
- Dernier épisode
- 12 Nov 2026
À propos du podcast
The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.
Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials.
Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.
This podcast is for you if:
- You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership
- You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness
- You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny
- You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources
What you will learn:
CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma.
Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.
New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.
Next Steps:
Get the 5-day CMC email course: https://smartbiotechscientist.com/#cmc
Visit the website: https://smartbiotechscientist.com
Email us: [email protected]
Épisodes 305
304: From Freezer to Bedside: Controlling Cryopreservation Variability in Cell Therapy Manufacturing with Sean Werner - Part 2
Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances? Biopreservation and cell processing are critical pain points in …
Notes de l’épisode
Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances? Biopreservation and cell processing are critical pain points in scaling advanced therapies for global distribution, with variables like cryoprotectant toxicity, transport stability, and automation dictating both cost and clinical success.
Sean Werner, CTO of Cell Processing at BioLife Solutions and former Sexton Biotechnologies leader, has seen the real cost when assumptions break down at scale. From container fractures to uncertain analytics, he’s guided teams through the frontline challenges of CMC and biologics.
Topics discussed:
- Why decentralized manufacturing and local storage might be the most practical path forward for delivering cell therapies globally (03:05)
- Key distribution chain challenges—how logistics complexity escalates with cross-border shipments and the risks of primary packaging failure (03:44)
- Regulatory expectations for transport validation and the importance of container integrity during shipping (04:49)
- The growing role of automation and closed systems in reducing manual steps, with a look at current capabilities and future directions (06:41)
- How more advanced analytics could unlock greater efficiencies and reduce manufacturing costs in cell therapy (07:49)
- Practical guidance for scientists looking to optimize freezing and thawing processes, including common assumptions to avoid (08:39)
- When it makes sense to use DMSO, risk management considerations, and whether DMSO-free really means safer (10:39)
- Long-term aspirations for room-temperature biopreservation and challenging industry assumptions about stability (13:13)
- The importance of process control and attention to detail in minimizing variability and improving clinical outcomes (14:44)
Smart insight: Sean Werner challenged the field to move beyond the cryo status quo: can we develop technologies for stable room temperature storage of living cells and biologics? While the hurdles are immense, questioning established dogma is the only route to transformative change. Above all, he warned, never treat biopreservation as an afterthought—the variability it introduces can undermine even the most promising therapies . As cell therapy matures, early and continual investment in process innovation and discipline will remain key.
If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry.
- Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh
- Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey Allen
- Episodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark Davison
- Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster
Connect with Sean Werner:
Website: www.biolifesolutions.com
LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/303: From Freezer to Bedside: Controlling Cryopreservation Variability in Cell Therapy Manufacturing with Sean Werner - Part 1
The integrity of individual cells is the cornerstone of breakthrough cell and gene therapies—but translating lab discoveries into clinical success demands mastering cryopreservation challenges rarely discussed …
Notes de l’épisode
The integrity of individual cells is the cornerstone of breakthrough cell and gene therapies—but translating lab discoveries into clinical success demands mastering cryopreservation challenges rarely discussed in depth.
Sean Werner, Chief Technology Officer of Cell Processing at BioLife Solutions,a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets, has dedicated his career to safeguarding cell viability from the lab bench through to clinical application.
Topics discussed:
- Sean Werner's unconventional career progression and early experiences in regenerative medicine (03:22)
- The critical role of cryopreservation in cell and gene therapy product quality (05:59)
- Biophysics of freezing: ice nucleation, supercooling, and their impact on cell viability (07:32)
- Hidden pitfalls in cryopreservation, including ice recrystallization and osmotic stress (07:43)
- Real-world challenges during clinical handling and thawing of cell therapies (11:18)
- Why the commonly used -1°C per minute freeze rate is not universally optimal (13:09)
- Difficulties in tracing clinical problems back to early cryopreservation choices (13:54)
- Importance of evaluating long-term cell function, not just post-thaw viability (15:08)
- Regulatory expectations around freeze-thaw processes in therapy manufacturing (16:34)
Smart insight: Success in cell therapy and advanced biologics is inseparable from mastery of cryopreservation. By adopting an experimental and data-driven mindset—questioning assumptions, customizing protocols, and measuring what truly matters—scientists can better fulfill that original promise: that a single cell, carefully protected, can change the course of medicine for patients worldwide.
If this episode has you rethinking freeze-thaw, here’s where to go next. Start with the science behind cryopreservation, then compare two takes on cryoprotectants: DMSO-free formulations and antifreeze-inspired chemistry.
- Episodes 241 - 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh
- Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO’s Toxic Side Effects with Jeffrey Allen
- Episodes 65 - 66: Freezing and Thawing Cells: the Science Behind Cryopreservation with Mark Davison
- Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster
Connect with Sean Werner:
Website: www.biolifesolutions.com
LinkedIn: https://www.linkedin.com/in/sean-werner-54688326/302: Why Rushing Cell Line Development Costs You Months Later: The Analytics-First CMC Strategy with Lars Stöckl and Lena Tholen - Part 2
Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy's success.Today, we feature Lars Stöckl and Lena …
Notes de l’épisode
Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy's success.
Today, we feature Lars Stöckl and Lena Tholen, industry experts from FyoniBio GmbH, who have deep experience guiding biotech teams through the maze of CMC development, troubleshooting both common and unusual product quality challenges.
Topics discussed:
- Key factors in selecting host cell lines and the importance of matching the platform to molecule complexity (02:34)
- The role of broad analytical assays early in cell line and pool development for better decision-making (03:34)
- Glycosylation, post-translational modifications, and analytical strategies for both standard antibodies and more complex biotherapeutics (05:10)
- When and how to conduct developability and manufacturability assessments, especially for novel or specialized molecules (06:55)
- Troubleshooting glycosylation and aggregation problems—when to tweak the process and when to reconsider the molecule (08:05)
- Importance of clear, direct communication with clients regarding manufacturability and process viability (09:32)
- Example of how different CHO cell lines can dramatically impact molecule outcome and company trajectory (12:08)
- Keeping pace with technological advances through collaboration, conferences, and feasibility studies with startups (13:55)
- The move toward customization over standardization in cell line and process development (18:07)
Smart insight: The future of bioprocess development lies in a customized, molecule-centric approach. Rather than relying on generic, pre-set development platforms, success comes from carefully matching cell lines, processes, and analytical methods to the unique requirements of each molecule. True innovation and commercial success arise from adapting everything—cell line, process, analytics—to the molecule at hand.
Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side.
- Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma Mostafa
- Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Lars Stöckl and Lena Tholen:
Website: www.fyonibio.com
LinkedIn:www.linkedin.com/in/dr-lars-stoeckl
LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a301: Why Rushing Cell Line Development Costs You Months Later: The Analytics-First CMC Strategy with Lars Stöckl and Lena Tholen - Part 1
How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?In this episode, David …
Notes de l’épisode
How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?
In this episode, David Brühlmann welcomes Lena Tholen and Lars Stöckl of FyoniBio GmbH—two scientists who’ve dedicated their careers to optimizing cell line and process development for biopharma clients.
Topics covered in this episode:
- The trend toward outsourcing CMC development and the reasons behind it for both large pharma and small biotechs (07:27)
- How specialized CDMOs innovate and continuously improve cell line development platforms, giving clients access to new options and efficiencies (10:36)
- Real-world experience navigating project pitfalls from discovery to clinical studies—including differences between cell lines and processes (13:38)
- The importance of retaining key activity assays and critical knowledge in-house—and the risks of over-reliance on consultants (15:04)
- Key factors that help biotech companies thrive when partnering with CDMOs, including internal expertise, flexibility, and milestone planning (17:32)
Smart insight: Product quality and success are designed in early through careful choices about cell lines, processes, and analytical strategies. Streamlined outsourcing and platform innovation can turbocharge development, but only when matched with committed, knowledgeable in-house leadership and measured, forward-thinking investment. The next time a CMC decision seems minor or a shortcut tempting, remember the long game—your product quality, speed to clinic, and future cost may all depend on it.
Lars and Lena’s main point is that early choices about the host cell line, the analytics and the partner decide what’s possible later on. The episodes below take that idea further. One looks at the mechanics of cell line development, one at why promising molecules fail to manufacture, and two at outsourcing CMC work from the sponsor’s side.
- Episodes 117 - 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist’s Guide to CDMO Selection with Sigma Mostafa
- Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Lars Stöckl and Lena Tholen:
Website: www.fyonibio.com
LinkedIn:www.linkedin.com/in/dr-lars-stoeckl
LinkedIn: www.linkedin.com/in/lena-tholen-80642a11a300: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 2
Is your process model gathering dust while real-world decisions march on without it? Many technically strong digital tools—no matter how powerful—end up sidelined in bioprocess development. Why is that, and …
Notes de l’épisode
Is your process model gathering dust while real-world decisions march on without it? Many technically strong digital tools—no matter how powerful—end up sidelined in bioprocess development. Why is that, and what does it actually take for digital modeling to earn its place at the lab bench?
In this episode, David Brühlmann sits down with Moritz von Stosch of HINA Bioventures, a scientist-turned-investor who’s navigated both the technology provider and pharma end-user sides. Moritz von Stosch brings firsthand insights from building digital solutions, deploying them in pharma, and evaluating what actually sticks when the clock is ticking and the stakes are high.
Topics discussed:
- The importance of starting with your purpose when selecting a modeling strategy (03:00)
- Experimental design: when to use factorial versus random space-filling designs, and the inherent biases each can introduce (04:22)
- The future of agentic workflows, AI, and autonomous labs in bioprocessing, including the importance and challenges of sensor technologies (06:02)
- Practical hurdles to implementing fully autonomous laboratories, and the non-obvious value humans still bring (09:09)
- Adapting mindsets for the evolving role of the bioprocess engineer in a more automated, agent-driven workflow (11:48)
- Advice for biotech professionals on how to assess the real value in new technologies versus hype, and the role of proprietary algorithms and company stability (13:33)
- How cultural factors, not just technology, shape the adoption of modeling and digital tools in biotech (16:02)
- Strategies to help the bioprocess community adopt more innovation while ensuring compliance in regulated environments (17:14)
- Three key takeaways for staying relevant—including generating data for tomorrow’s questions and balancing curiosity, experimentation, and oversight (19:14)
Smart insight: Three takeaways from Moritz von Stosch:
- Generate data for tomorrow’s questions, not just today’s.
- Be curious—try, adapt, don’t over-plan.
- Stay relevant: Use digital tools but keep your human edge (creativity, critical thinking).
To keep exploring how modeling and prior knowledge can speed up process development, check out these related conversations:
- Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
- Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
- Episodes 277 - 278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano
- Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
Connect with Moritz von Stosch:
Website: www.hinabioventures.com
LinkedIn: www.linkedin.com/in/movosto299: Where Bioprocess Models Deliver and Where They Overpromise: Choosing Between Hybrid, Mechanistic, and Machine Learning with Moritz von Stosch - Part 1
Are you frustrated with reinventing the wheel every time a new molecule enters bioprocess development? Is there a better way to harness data and modeling to accelerate breakthroughs in biotech? The …
Notes de l’épisode
Are you frustrated with reinventing the wheel every time a new molecule enters bioprocess development? Is there a better way to harness data and modeling to accelerate breakthroughs in biotech? The bioprocessing industry is constantly searching for ways to streamline development, reduce costs, and speed new therapies to market—yet leveraging existing knowledge remains a significant challenge.
In this episode, David Brühlmann welcomes Moritz von Stosch, partner at HINA Bioventures and a pioneer in digital bioprocess development. Spanning roles from academic research in hybrid modeling to solution design at DataHow and now biotech investment, Moritz von Stosch’s journey traces how mechanistic, hybrid, and machine learning models have (and haven’t) changed process development over the last two decades.
Topics discussed:
- Moritz von Stosch’s career: from early interest in modeling to investment in digital bioprocess tools (03:36)
- The reality and limitations of platformization and knowledge reuse in large pharma (07:37)
- Historical context and effectiveness of QbD (Quality by Design) and PAT (Process Analytical Technology) initiatives (10:24)
- Where modeling can reliably deliver value today in process and clinical development—and where it still overpromises (12:17)
- The importance of starting to build models early and collecting data that can be reused and repurposed across the process lifecycle (14:17)
- Approaches to transferring learning between molecules, cell lines, platforms, and the fundamental limitations of this transfer (16:40)
- Opportunities and difficulties in transferring process knowledge across scales (from microtiter plates to large bioreactors) (18:31)
Smart insight: David Brühlmann and Moritz von Stosch agree that models are only useful when they are built on reliable data and interpreted with expert judgment. Models can help biotech teams make better decisions, but they don’t replace human expertise. The real value comes from looking at the whole process, focusing on the data that matters, and making sure knowledge is shared effectively. This can help teams improve bioprocess development and bring new treatments to patients sooner.
To keep exploring how modeling and prior knowledge can speed up process development, check out these related conversations:
- Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
- Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
- Episodes 277 - 278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano
- Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
Connect with Moritz von Stosch:
Website: www.hinabioventures.com
LinkedIn: www.linkedin.com/in/movosto298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2
The entire public record of antibody affinity data comes to about half a million measurements, and by David Younger's estimate, upwards of 75% of it is AlphaSeq data from his own company's …
Notes de l’épisode
The entire public record of antibody affinity data comes to about half a million measurements, and by David Younger's estimate, upwards of 75% of it is AlphaSeq data from his own company's publications. His conclusion is that no single company can close the gap alone. So he is asking pharma and AI labs to pay for an experiment and share every result with the other members.
In Part 2 of this two-part conversation, David Brühlmann talks with Younger, founding CEO of A-Alpha Bio, whose AlphaSeq platform uses engineered yeast to measure protein interactions at scale. Part 1 set out the shortfall: about 10,000 antibody-antigen structures in the Protein Data Bank against a need of hundreds of thousands to millions. Here Younger explains how the consortium keeps proprietary targets out of the shared pool, who has joined, and why he believes it differs from federated learning.
Topics discussed:
- Challenges faced by individual companies in generating sufficient data for effective AI models (02:17)
- How a data consortium enables pre-competitive data sharing while protecting proprietary information (06:13)
- Profiles of ideal consortium members and examples of current participants from pharma and AI model builders (08:36)
- The consortium’s current focus on VHH antibodies and plans for expansion to broader datasets and applications by 2030 (10:00)
- Comparison between the consortium approach and federated learning models in data sharing and collaboration (12:01)
- The main takeaways about the quantity and quality of data needed for machine learning in protein engineering (14:09)
Smart insight: As David Younger envisions it, successful maturation of these consortia could fundamentally shift the field by 2030. Multiple consortia could address different scaffolds, data types, and problem statements, alleviating the bottleneck that has long constrained progress. The hope is that abundant, high-quality data will enable breakthrough therapeutic advancements while revealing new gaps that, in turn, inspire the next wave of innovation. Notably, David Younger sees collaboration—not just data scale—as the true secret weapon. Unlike federated learning, consortia incentivize members to share not just data, but experimental insights and best practices, effectively lifting all boats and accelerating collective progress.
Curious how others are tackling the data problem in protein design? These episodes pick up right where David Younger leaves off.
- Episodes 185 - 186: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus
- Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 219 - 220: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger
Connect with David Younger
Company website: www.aalphabio.com
LinkedIn: www.linkedin.com/in/david-a-younger/
Data Atlas website: www.atlas.aalphabio.com297: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 1
The Protein Data Bank holds about 10,000 antibody-antigen structures and grows by roughly 1,000 a year. David Younger's scaling work suggests that generalizable de novo antibody design needs hundreds of …
Notes de l’épisode
The Protein Data Bank holds about 10,000 antibody-antigen structures and grows by roughly 1,000 a year. David Younger's scaling work suggests that generalizable de novo antibody design needs hundreds of thousands to millions. At that pace, even 200,000 structures is nearly two centuries away.
In this episode, David Brühlmann hosts David Younger, founding CEO of A-Alpha Bio and the mind behind the AlphaSeq platform. Trained at the intersection of synthetic biology and computational protein engineering, David Younger cut his teeth at the Institute for Protein Design and sharpened his focus on the stubborn gap between theoretical promise and practical performance. His approach rewrites the rules of data generation—scaling up both the volume and the insight from protein interaction data to deliver the kind of information AI needs to actually make an impact in therapeutic design.
Topics discussed:
- Bottlenecks caused by insufficient and low-quality data in AI-enabled protein engineering (02:53)
- The limitations of traditional protein discovery methods and the persisting role of serendipity in antibody development (08:02)
- An overview of the AlphaSeq platform and how it enables large-scale measurement of protein interactions using engineered yeast (10:50)
- The differences between measuring protein-protein affinities with conventional techniques and AlphaSeq’s batch approach, including cost and speed advantages (16:54)
- Strategies for generating training data for machine learning models in protein engineering, including the need for structural and affinity data (18:23)
- The value and limitations of the Protein Data Bank (PDB) in training de novo design models (20:17)
- The challenge of benchmarking foundational models for protein engineering and the need for universal industry standards (23:11)
Smart insight: The future of biotherapeutic innovation is intertwined with a simple truth: more and better data unlock AI’s true potential. With breakthrough wet-lab technologies like AlphaSeq, and commitment to openness and benchmarking, the dream of efficient, precise, and truly rational protein engineering may soon become reality. The next big leap in biotech is not just smarter algorithms—but the scale, quality, and transparency of the data that powers them.
Curious how others are tackling the data problem in protein design? These episodes pick up right where David Younger leaves off.
- Episodes 185 - 186: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus
- Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 219 - 220: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger
Connect with David Younger
Company website: www.aalphabio.com
LinkedIn: www.linkedin.com/in/david-a-younger/
Data Atlas website: www.atlas.aalphabio.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2
Cardiovascular disease has long been managed by slowing its relentless progression. But Matthew O'Connor, CEO of Scientific Affairs at Cyclarity Therapeutics, is betting on an outright paradigm shift …
Notes de l’épisode
Cardiovascular disease has long been managed by slowing its relentless progression. But Matthew O'Connor, CEO of Scientific Affairs at Cyclarity Therapeutics, is betting on an outright paradigm shift: treating atherosclerotic plaque with therapies designed to actively reverse disease, not simply manage symptoms or risk.
In this episode, David Brühlmann explores the strategy, regulatory journey, and manufacturing realities behind Cyclarity's unconventional cyclodextrin-based approach—a molecule sitting at the crossroads of small and large molecule drug development.
Topics discussed:
- Insights into the company's clinical development progress, including completion of a first-in-human study and what comes next (02:47)
- How the FDA views drugs that don't fit traditional categories and how this influences development pathways (04:35)
- The challenges and considerations in demonstrating efficacy for drugs designed to reduce heart attacks and strokes (05:22)
- Cost considerations in manufacturing the cyclodextrin dimer and how it compares to biologics and GLP-1 drugs (08:14)
- Vision for how cardiovascular disease may be diagnosed and treated a decade from now, including the role of imaging and prevention (10:24)
- Broader implications for treating age-related diseases by targeting toxic metabolites in the body (14:25)
- Why next-generation therapeutics may be built not by sticking to old modalities but by tackling root causes with custom solutions (16:10)
- Reflections on making new drugs both safe and fundamentally beneficial, minimizing side effects (17:10)
Smart insight: Start with the problem, not the modality. Matthew O'Connor argues that instead of defaulting to an antibody, a small molecule or a gene therapy, developers should build a custom solution to the problem they're trying to solve. A drug that suppresses a pathway across the whole body brings side effects you have to manage. A drug that removes something harmful, like oxidized cholesterol, can have side effects that are actually beneficial. His goal for the next generation of drugs is ones that simply make people healthier.
When a drug is too big to be a small molecule and too small to be a biologic, every CMC decision gets harder. These episodes look at what it takes to develop, characterize and manufacture a modality that doesn't fit an existing box.
- Episodes 281 - 282: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar
- Episodes 207 - 208: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo
- Episodes 197 - 198: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
Connect with Matthew O'Connor:
Website: www.cyclaritytx.com
LinkedIn: www.linkedin.com/in/droki
Email: [email protected]Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
295: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 1
Why does CMC development still expect every drug to be one molecule with one peak, when new therapeutics don't always fit neatly into existing regulatory or chemical categories?Matthew O'Connor, CEO …
Notes de l’épisode
Why does CMC development still expect every drug to be one molecule with one peak, when new therapeutics don't always fit neatly into existing regulatory or chemical categories?
Matthew O'Connor, CEO of Scientific Affairs at Cyclarity Therapeutics, is developing a drug that sits between a small molecule and a biologic. On the Smart Biotech Scientist Podcast, Matthew shared how his team engineered a cyclodextrin dimer that binds and removes 7-ketocholesterol, an oxidized form of cholesterol that builds up in artery plaque and is linked to a higher risk of heart attack and stroke.
Topics discussed:
- Matthew O'Connor's motivation for focusing on aging and molecular damage (03:39)
- The biological problem of oxidized cholesterol buildup and its role in atherosclerosis (04:42)
- Mechanism of action: how the cyclodextrin binds and removes 7-ketocholesterol (06:23)
- Approaches to designing a highly specific cyclodextrin therapeutic (09:14)
- The "medium-sized molecule" characteristics and the question of regulatory classification (12:16)
- Why cyclodextrin starting material is cheap and not a manufacturing bottleneck (15:37)
- Manufacturing strategies and the role of specialist CDMOs in complex carbohydrate chemistry (17:04)
- Methods for demonstrating identity and consistency in isomeric mixtures (18:43)
- Drug formulation considerations and why an injectable route is necessary (21:46)
Smart insight: Matthew O'Connor's work shows what happens when you start with the problem rather than the drug format. His team's cyclodextrin dimer doesn't fit neatly as a small molecule or a biologic, and that makes manufacturing, analytics and regulatory work harder. But if it can remove oxidized cholesterol from the body, it could help reverse plaque instead of just slowing it down.
When a drug is too big to be a small molecule and too small to be a biologic, every CMC decision gets harder. These episodes look at what it takes to develop, characterize and manufacture a modality that doesn't fit an existing box.
- Episodes 281 - 282: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar
- Episodes 207 - 208: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo
- Episodes 197 - 198: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
Connect with Matthew O'Connor:
Website: www.cyclaritytx.com
LinkedIn: www.linkedin.com/in/droki
Email: [email protected]Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
294: Is CFD Overkill for Your Scale-Up? Why It Belongs in Every Biotech Scientist's Toolkit with Christian Witz - Part 2
Scale-up doesn't fail because the science was wrong. It fails because a cell's environment in a shake flask has little in common with its environment in a bioreactor. Christian Witz has spent years …
Notes de l’épisode
Scale-up doesn't fail because the science was wrong. It fails because a cell's environment in a shake flask has little in common with its environment in a bioreactor. Christian Witz has spent years building the tools to close that gap: simulating exactly what a cell experiences as it moves from bench to plant, before a single liter is wasted finding out the hard way.
Continuing from Part 1, David Brühlmann and Christian Witz, CEO and founder of SimVantage, go deeper into how CFD moves from theory to daily practice: validating simulation results, scaling real cell therapy and Streptomyces processes, and an active FDA-backed project on residence time distribution in continuous bioprocessing.
Topics discussed:
- Why data validation is crucial in CFD simulations and how to interpret and trust simulation results (02:39)
- Real-world examples of scaling up from shake flasks to stirred tank reactors using CFD, including specific collaborations and cell therapy case studies (05:40)
- Technical and validation challenges in simulating fluid dynamics in shake flasks and integrating these results into scale-up strategies (08:14)
- Ongoing FDA-backed project to model residence time distribution in continuous bioprocessing and its regulatory significance (11:49)
- The increasing openness of regulators like the FDA to include CFD data in submissions and relevant guidelines for simulation credibility (13:23)
- Advice for small biotech teams on when and how to start using CFD in CMC development and scale-up planning (15:06)
- Insights on the future of bioprocessing, including virtual scale-up, digital reactor repositories, and the democratization of CFD tools (18:20)
Smart insight: Christian Witz advised that teams begin CFD modeling as early as concept development. CFD not only helps choose the right equipment—even when working with contract manufacturers—but creates a digital process record that reduces experimental burden, shortens timelines, and impresses investors with its risk mitigation.
If this conversation got you rethinking your scale-up strategy, here are a few past episodes that go deeper on the pieces Christian touched on:
- Episodes 91 - 92 : Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
- Episodes 245 - 246: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei
- Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
- Episode 243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework
Connect with Christian Witz:
Website: www.simvantage.com
Christian’s LinkedIn: www.linkedin.com/in/christian-witz-84aa9b162/
Christian’s email: [email protected]Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
293: Is CFD Overkill for Your Scale-Up? Why It Belongs in Every Biotech Scientist's Toolkit with Christian Witz - Part 1
You've perfected your process at the bench. Now comes the part that keeps CMC scientists up at night: will it still work at 2,000L? Right now, most teams find out the hard way, through failed runs, wasted …
Notes de l’épisode
You've perfected your process at the bench. Now comes the part that keeps CMC scientists up at night: will it still work at 2,000L? Right now, most teams find out the hard way, through failed runs, wasted batches, and months of delay to patients waiting on a therapy. Christian Witz believes there's a better way: use computational fluid dynamics to see how your cells will actually behave at full scale before you ever run the process, and stop treating scale-up as a guessing game.
On this episode of the Smart Biotech Scientist Podcast, David Brühlmann talks with Christian, founder of SimVantage, about why he treats CFD as a tool every process engineer should use directly, not something you outsource to a specialist. Christian's path into biotech ran through heat pump simulations and GPU-based particle flow modeling before he rebuilt a legacy Fortran bioreactor simulation program in modern C++ and CUDA, work that became the foundation of SimVantage.
Topics discussed:
- Christian’s path from simulating heat pumps and particle flows to pioneering GPU-based bioreactor simulations (03:54)
- The surprising lack of full equipment characterization in the biotech industry compared to fields like oil, gas, and iron & steel (06:40)
- The interdisciplinary challenges and steep learning curve when entering biotech from other industries (08:07)
- Why academic spinouts matter and the practical realities of founding a company based on university-developed software (09:44)
- Reasons behind CFD’s low adoption in bioprocessing—perceived complexity, need for specialists, and historical limitations in algorithms and computing power (11:58)
- How recent advances in GPU power, algorithms, and cloud computing remove barriers for routine use of CFD in process development (14:35)
- Strategies for characterizing and scaling processes across various reactor types, from shake flasks to manufacturing reactors (16:39)
- Practical considerations and limitations when setting up comprehensive CFD characterizations, including simulation parameter choices (19:49)
Smart insight: The degree of reactor characterization depends on a company’s needs. Startups might analyze a scale-up project once, while contract manufacturers—handling diverse products—benefit from comprehensive, reusable characterization across all reactors and operating conditions. Simulations are guided by physics (density, viscosity, surface tension) rather than biological specifics, allowing quick adaptation to new media or cell types.
If this conversation got you rethinking your scale-up strategy, here are a few past episodes that go deeper on the pieces Christian touched on:
- Episodes 91 - 92 : Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
- Episodes 245 - 246: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei
- Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
- Episode 243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework
Connect with Christian Witz:
Website: www.simvantage.com
Christian’s LinkedIn: www.linkedin.com/in/christian-witz-84aa9b162/
Christian’s email: [email protected]Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
292: The Fool's Game That Became Standard Practice: Perfusion, the ATF, and What Changed with John Bonham-Carter - Part 2
Biotech founders often pour everything into building the “perfect” product only to realize their real customers have walked out the door. Chasing perfection can burn money and stall even the most promising CMC …
Notes de l’épisode
Biotech founders often pour everything into building the “perfect” product only to realize their real customers have walked out the door. Chasing perfection can burn money and stall even the most promising CMC innovations.
In this episode, David Brühlmann continues his conversation with biotech entrepreneur and investor John Bonham-Carter. John shares his insights on the realities of building and scaling successful biotools companies, from the challenges of fundraising and the importance of authentic storytelling, to knowing when to stop perfecting a product and start selling.
Topics discussed:
- How fundraising is less about money and more about the story, team, and real commitment behind a startup (02:33)
- Practical advice for founders: obsess over the customer, not just the technology (07:14)
- The dangers of spreading yourself too thin as a startup founder and lessons from parenting applied to startups (07:09)
- Choosing business partners and collaborators whose skills complement your own—and making peace with imperfection (10:10)
- John’s approach to building teams and why accepting mediocrity in some areas can lead to collective excellence (11:16)
- The story behind John joining Stellion Biosystems, and what makes their cell counting technology different in the market (11:51)
- Using creative, low-budget tactics for visibility—why John chose a lizard mascot for Stellion Biosystems (15:19)
- Thoughts on when (if ever) to stop and the value of keeping multiple life and career doors open (17:26)
- John’s main takeaway: “Try everything”—professional advice drawn from experience (and Zootopia) (19:01)
Smart insight: John leaves us with a simple yet powerful credo: “Try everything.” In biotech, that means embracing experimentation not just in the lab, but in business strategy, partnerships, hiring, and technology adoption. By collaborating, iterating, and listening closely to customers, you can grow, succeed, and—perhaps—build something that truly makes a difference. In a field where the only constant is change, remember: launch before you’re ready, find your people, and keep your story genuine.
Some ideas are ahead of their time; a few people make a career of being early. This is part bioprocess history, part founder's playbook: why the best technology doesn't automatically win, how to move a conservative industry, and when to sell rather than scale. To go further on both the technology and the business behind it:
- Episodes 191 - 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan
- Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
- Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
- Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
Connect with John Bonham-Carter:
Website: www.stellion-biosystems.com
LinkedIn: www.linkedin.com/in/johnbcFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
291: The Fool's Game That Became Standard Practice: Perfusion, the ATF, and What Changed with John Bonham-Carter - Part 1
Biotech loves talk of disruptive technology, but few have repeatedly shifted the industry's direction. This episode of the Smart Biotech Scientist Podcast focuses on an idea once dismissed as a fool's …
Notes de l’épisode
Biotech loves talk of disruptive technology, but few have repeatedly shifted the industry's direction. This episode of the Smart Biotech Scientist Podcast focuses on an idea once dismissed as a fool's game: process intensification through perfusion—now the backbone of leading biomanufacturing platforms.
Meet John Bonham-Carter, a serial entrepreneur whose fingerprints are on some of biotech's most transformative tools. From putting the once-ignored ATF system and perfusion on the global stage to pushing intensified cell therapy bioprocessing with ERBI, John's story isn't about chasing the next big exit. Instead, it's about spotting unmet needs and building and selling biotools companies more than once.
Topics discussed:
- The story behind the ATF system, and how John Bonham-Carter and his collaborators convinced a conservative industry to adopt perfusion (04:43)
- Early career influences, including family ties to bioprocess equipment manufacturing (05:03)
- Reflections on the biotech industry’s culture of collaboration and the dual motivation to deliver medicines and achieve commercial success (07:18)
- Realities of scaling a startup, trading income for equity, and the role of persistence in sales (09:34)
- Lessons learned from global travel and building professional networks in biotech (10:16)
- The importance of recognizing what drives different biotech companies to adopt new technology (12:25)
- The transition from ATF to co-founding Erbi, a bioprocessing startup focused on small-volume cell therapy (19:05)
- Strategic acquisitions: experiences of being acquired by Repligen and Merck Millipore (22:50)
- Advice for founders on whether to build a company for exit or long-term operation (23:07)
- The limits of leading with technology, and why customer understanding is critical to success (26:10)
Smart insight: For founders, John Bonham-Carter offers practical guidance anchored in self-awareness. Should you build a company for the long haul or for acquisition? The answer: “There isn’t really a right answer...it is, what is the life you want to lead?” Some entrepreneurs thrive at the scale of ten-person teams and relish the handoff to a strategic acquirer. Others yearn to build and steer a 200-person enterprise. Regardless, serving customers and employees well, and being attuned to the market’s shifting demands, matter most. Exit opportunities arise from building value and strategic fit—not from fixating on selling out.
Some ideas are ahead of their time; a few people make a career of being early. This is part bioprocess history, part founder's playbook: why the best technology doesn't automatically win, how to move a conservative industry, and when to sell rather than scale. To go further on both the technology and the business behind it:
- Episodes 191 - 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan
- Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
- Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
- Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
Connect with John Bonham-Carter:
Website: www.stellion-biosystems.com
LinkedIn: www.linkedin.com/in/johnbcFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
290: Batch-to-Batch Variability Is a Design Failure, Not the Norm with Sandra Núñez - Part 2
What if building a world-class biotech company didn’t require owning a single piece of manufacturing equipment or even a lab of your own?Most startups obsess over bricks, mortar, and stainless steel. Not Sandra …
Notes de l’épisode
What if building a world-class biotech company didn’t require owning a single piece of manufacturing equipment or even a lab of your own?
Most startups obsess over bricks, mortar, and stainless steel. Not Sandra Núñez. She’s challenging the status quo as CEO of Amela Biosciences by running a “virtual plant” model: zero in-house production, everything outsourced, and agility baked into every decision. It’s a bold experiment in redefining what a biotech company can look like. One that’s already delivering real, animal-free products to customers today.
Topics discussed:
- Key considerations and pitfalls in tech transfer from academic labs to external CDMO partners (02:34)
- The reasoning behind choosing a virtual plant model with no in-house manufacturing (04:57)
- Criteria for selecting external manufacturing partners, including technical capabilities and cultural fit (06:28)
- Stakeholder communications and managing misconceptions about outsourced manufacturing (07:44)
- Process development challenges when scaling products for commercial use, including impurity profile and scalability of purification methods (08:53)
- Early preparations for future GMP manufacturing and building a foundation for regulatory compliance (11:20)
- The impact of regulatory shifts (like the FDA Modernization Act 2.0) on manufacturing strategy and product reproducibility (12:47)
- Hopes for the company’s future role in the transition to animal-free and regenerative medicine (14:19)
- Practical advice for startup founders considering a leap from corporate biotech to entrepreneurship (15:09)
- Reflections on the importance of addressing batch-to-batch variability and building reproducible systems (16:40)
Smart insight: Don’t accept batch-to-batch variability. Reproducibility is non-negotiable. Batch-to-batch variability, whether in raw materials or process design, is a critical risk that forward-thinking should design out, not accept as inevitable. As Sandra concludes, reproducibility isn’t just a lab problem, it’s a company-building problem, one that shapes strategy, manufacturing partnerships, and regulatory success.
Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory:
- Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker
- Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
- Episodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet
- Episodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher
Connect with Sandra Núñez:
Website: www.amelabiosciences.com
Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag
Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch
Sandra’s email: [email protected]Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
289: Batch-to-Batch Variability Is a Design Failure, Not the Norm with Sandra Núñez - Part 1
Batch-to-batch variability isn’t just a minor annoyance in bioprocess development; it’s often a systemic design flaw hiding in plain sight.That’s the challenge Sandra Núñez, CEO of Amela Biosciences, set out to …
Notes de l’épisode
Batch-to-batch variability isn’t just a minor annoyance in bioprocess development; it’s often a systemic design flaw hiding in plain sight.
That’s the challenge Sandra Núñez, CEO of Amela Biosciences, set out to eliminate. Drawing on 15 years across Lonza, Medinova, Baxalta, and Biogen, she’s engineered a new generation of animal-free, recombinant protein matrices that promise researchers experimental consistency on demand.
Topics discussed:
- The widespread issue of batch-to-batch variability and why Sandra argues it’s a design failure, not the norm (02:49)
- The mechanics and biological tunability of Amela’s engineered protein matrices, and how this technology works (06:34)
- How Amela’s recombinant protein bioinks differ from traditional animal-sourced extracts, enabling reproducibility (08:53)
- Manufacturing insights: why the proteins are relatively straightforward to produce for research use (12:05)
- Engaging with users to optimize and customize protein matrices for diverse tissue and assay applications (13:33)
- The creation and use of protein libraries for specific user requirements and the flexibility this provides (16:20)
- Definitions and roles of ‘bioinks’ in tissue modeling and 3D cell culture (16:52)
Smart insight: Reproducibility remains the cornerstone of reliable science. With innovative platforms like Amela Biosciences’ engineered protein matrices, the future of tissue engineering and in vitro biology looks not just reliable, but radically empowering. If you’re striving for consistency, customizability, and cutting-edge technology in your workflows, the era of animal-free, batch-consistent bioinks has arrived.
Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory:
- Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker
- Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
- Episodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet
- Episodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher
Connect with Sandra Núñez:
Website: www.amelabiosciences.com
Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag
Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch
Sandra’s email: [email protected]Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
288: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 2
Manufacturability challenges in biotech are becoming more complex as therapies become more potent, formats diversify, and timelines compress across the industry.On this episode, David Brühlmann sits down with …
Notes de l’épisode
Manufacturability challenges in biotech are becoming more complex as therapies become more potent, formats diversify, and timelines compress across the industry.
On this episode, David Brühlmann sits down with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. Sigma brings deep expertise in early-stage CMC decision-making and has guided countless programs—from upstart startups to established pipelines—through the traps and trade-offs of process development. Her ground-floor perspective spans in silico modeling, innovative cell line engineering, and the gritty realities of tech transfer.
Key topics discussed:
- Practical advice for startups on selecting robust cell lines and avoiding long-term lock-in to problematic platforms (03:07)
- Managing risks in process development, such as high oxygen demand and filter loading, before tech transfer to manufacturing (04:47)
- The value of pressure testing bioprocesses at scale and identifying potential failure modes, including filter clogging and narrow feeding windows (07:41)
- Balancing speed, robustness, and regulatory expectations when advancing new molecules (09:23)
- How fast-tracking from transfection to IND is changing timelines, and the associated risks of accelerated development (09:54)
- Trends and caution in applying AI and in silico tools to protein and process modeling, and the limits of digital solutions (12:01)
- What first-time founders need to get right, including early analysis of molecular issues and careful cell line selection (15:48)
- Shifting modality trends—growing numbers of ADCs/XDCs, more complexity, and the move toward smaller scale and more potent molecules (16:55)
- The overarching lesson: invest early in the areas you cannot change later—especially cell line and understanding of molecule challenges (18:23)
Smart insight: Startup founders often wonder which fires to fight first. Sigma’s advice: focus on deep molecular assessment and making informed, scalable cell line choices above all else. These are the “few things you cannot change later” and the investments that separate enduring programs from cautionary tales.
This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent.
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
- Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa
Connect with Sigma Mostafa:
Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817
KBI website: https://www.kbibiopharma.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
287: Why the Cell Line Is the CMC Decision You Don't Get to Undo with Sigma Mostafa - Part 1
A breakthrough in drug discovery can be derailed in an instant if manufacturability is left as an afterthought. Too many biotech programs hit bottlenecks at scale-up because key decisions in cell line and …
Notes de l’épisode
A breakthrough in drug discovery can be derailed in an instant if manufacturability is left as an afterthought. Too many biotech programs hit bottlenecks at scale-up because key decisions in cell line and process development get kicked down the road.
On the Smart Biotech Scientist Podcast, David Brühlmann spoke with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. She’s spent 25+ years converting early-stage discoveries into commercial biomanufacturing success and she’s adamant: manufacturability decisions belong at the candidate selection stage, not after.
Topics discussed:
- Why manufacturability should be assessed at the candidate selection stage, not later (03:02)
- Sigma’s background in bringing math and biology together and her path into bioprocess engineering (04:18)
- The "art" and complexity of bioprocess development, especially with new molecule types (05:54)
- A case study of how switching cell lines revealed hidden manufacturability issues (07:33)
- Key properties affecting manufacturability, such as aggregation and thermal stability (10:10)
- Reasons companies delay manufacturability assessments—timing pressure, costs, and lack of early deep characterization (11:02)
- Why CMC should be integrated from day one and concerns with treating scalability as 'just' engineering (12:08)
- Critical decisions and pitfalls in cell line development, including robustness, media choices, and adapting after the master cell bank is made (12:48)
- Regulatory aspects of cell line development: demonstrating clonality, avoiding animal source materials, and documentation requirements (15:04)
Smart insight: Manufacturability is not just a box for the CMC team. It’s a proactive mindset, to be embraced from day one. Early, cross-functional scrutiny—examining both molecule and cell line—preempts disasters during scale-up and accelerates timelines to market while minimizing costly surprises.
This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent.
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
- Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa
Connect with Sigma Mostafa:
Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817
KBI website: https://www.kbibiopharma.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
286: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 2
What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech’s ambitions are often limited not …
Notes de l’épisode
What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech’s ambitions are often limited not by vision, but by the real-world bottlenecks of host cell lines and the unpredictability of post-translational modifications.
Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has made a career out of asking impossible questions about glycosylation, cell line selection, and the hidden machinery at work inside every productive cell. He’s moved beyond academic curiosity—translating discoveries into applications and even launching a company, Augment Biologics, that’s taking glycoengineering from theory to practice.
Topics discussed:
- A proximity proteomics approach to identify supporting machinery for challenging-to-express proteins like rituximab (02:36)
- Findings from expressing the full human secretome in CHO cells, and the correlation between host cell gene expression and protein productivity (05:00)
- Clarifying when host cell characteristics matter more than the protein construct itself (05:46)
- Emerging evidence that protein sequence and structure influence glycosylation patterns (contrary to previous dogma) (06:49)
- Engineering point mutations to precisely tune glycan features for improved therapeutic efficacy (09:25)
- The vision and activities of Augment Biologics in custom glycosylation control for drug discovery (10:32)
- The importance and barriers to open data sharing in bioprocessing, and thoughts on overcoming them (11:11)
- The shifting landscape as technology advances and the need for high-quality, annotated data (13:54)
If this got you thinking about the data already sitting in your freezer, and what it would take to actually use it, start here. These four conversations dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.
- Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
- Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
- Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain
- Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres
If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty
Connect with Nathan Lewis:
Website: www.lewislab.uga.edu
LinkedIn: www.linkedin.com/in/nathanelewisFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
285: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 1
Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs.Nathan Lewis …
Notes de l’épisode
Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs.
Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has a clear message: actionable data is now within reach thanks to hybrid modeling, advanced study design, and AI as a true scientific collaborator.
Topics discussed:
- Rethinking the dogma: controlling protein glycosylation quality from the inside out, not just by bioprocess conditions (03:00)
- Nathan Lewis’s journey into science and bioprocessing, from unexpected college choices to pivotal advances in CHO cell engineering (05:12)
- The evolution of omics in bioprocessing: why actionable insights, not just big datasets, should be the goal (10:49)
- Strategic advice for structuring, annotating, and making old and new datasets ready for AI and LLM analysis (17:34)
- The balance between mechanistic and machine learning models—when each makes sense, and why hybrid modeling is gaining ground (22:20)
- The current and future role of digital twins in process development and why foundation models and data consortia matter for scalability (26:24)
Smart insight: The real revolution isn’t in making new data, but in unlocking the value of what already exists. Advances in AI, hybrid modeling, and collaborative standards promise to turn decades-old data into a catalyst for innovation—enabling faster, smarter, and more reliable bioprocess development.
If this got you thinking about the data already sitting in your freezer — and what it would take to actually use it — start here. These four dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.
- Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
- Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
- Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain
- Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres
If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty
Connect with Nathan Lewis:
Website: www.lewislab.uga.edu
LinkedIn: www.linkedin.com/in/nathanelewisFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
284: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 2
“Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound …
Notes de l’épisode
“Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound too good to be true.
In Part 2 of this conversation, Kent rejoins the Smart Biotech Scientist Podcast to address that skepticism head-on, unpack how subclone variability and bispecific antibody purity concerns shape customer trust, and share what it actually took to move Biolinco from a Johns Hopkins postdoc project to a company with its first paying customer.
In this episode:
- Common pushbacks and questions from industry regarding new cell line development technologies (03:18)
- Practical advice for resource-constrained startups developing cell lines, emphasizing efficiency and data quality over brute force automation (08:42)
- The role and value of DNA barcoding in screening and developing robust cell lines for therapeutics (08:56)
- Lessons learned from translating scientific innovation into a commercial product, including securing early support and customer trust (10:27)
- Insights on adapting messaging, leveraging feedback, and understanding market needs as part of the entrepreneurial process (13:52)
- Key differences between academic research and industry requirements for reliable, repeatable biotech tools (15:26)
- Kent’s most important takeaway for successful cell line development: focus on collecting the right data at the right scale for informed decisions (17:14)
Smart insight: Translating innovations from academia to industry brings a new wave of challenges. Kent describes the “valley of death” separating a publishable prototype from a reliable, commercial-grade product. Academic success is often tied to novelty, publications, and grants, while industry demands repeatability, robustness, and consistent performance across labs and operators. Securing early champions and funding, iterating based on tough industry feedback, and building trust with initial partners all require resilience, and a willingness to pivot as needed. Feedback, even when harsh, becomes a “gift” that helps refine the product and business model. The secret is not a single breakthrough, but adaptability and relentless customer focus.
If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.
- Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
- Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
Connect with Kent Rapp:
LinkedIn: www.linkedin.com/in/kent-rapp
Biolinco website: www.biolinco.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
283: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 1
What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them?Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that …
Notes de l’épisode
What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them?
Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies.
This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of Biolinco, an entrepreneur who’s turning the classic approach to cell line development inside out. Drawing from his background in chemical engineering and his work in biomanufacturing at Johns Hopkins University, Kent teamed up with DNA barcoding experts to pioneer a new workflow: barcode every cell, pool them, and track their true performance in the environment that matters.
Topics discussed:
- The pitfalls of brute-force screening in traditional cell line development (03:05)
- Kent’s background and how he was drawn to combine science, startups, and biomanufacturing (04:37)
- Overcoming discrepancies between small-scale and large-scale screening environments (08:30)
- How DNA barcoding allows for high-resolution, pooled clone screening (10:34)
- Sensitivity advantages of sequencing over plate-based detection (14:21)
- Methodology for tracking and recovering individual high-performing clones from pools (15:13)
- Impact on speed and workflow efficiency in cell line development (17:31)
- Regulatory and safety considerations related to DNA barcodes in cell lines (19:04)
Smart insight: According to Kent, biotech as an industry has a tendency to "automate problems instead of solve them". Rather than addressing the root causes—like lack of meaningful measurements at relevant scales—companies often throw more robots and more plates at the issue, hoping brute force will finally yield the magical clone. But real process improvement requires a rethinking of what is being measured and how those insights are generated—not just a higher throughput of the same flawed assay.
If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.
- Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
- Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill
- Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
- Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
Connect with Kent Rapp:
LinkedIn: www.linkedin.com/in/kent-rapp
Biolinco website: www.biolinco.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
282: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 2
Your active ingredient is the nucleic acid. So why does a proteolipid vehicle filing include viral clearance studies, stability data and full characterisation of a membrane protein that is not the drug? Because …
Notes de l’épisode
Your active ingredient is the nucleic acid. So why does a proteolipid vehicle filing include viral clearance studies, stability data and full characterisation of a membrane protein that is not the drug? Because that protein sits on the particle surface, and a component nobody has filed before is the agency's problem regardless of what you call it.
Proteolipid vehicles (PLVs), the platform Jitendra Kumar works on as Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, represent a novel frontier in drug delivery, Instead of being taken up into an endosome and having to escape it, a PLV fuses with the cell membrane and releases cargo straight into the cytosol. That opens targets and patient groups that liver-tropic lipid nanoparticles and viral vectors have struggled to reach, and it leaves Kumar building a regulatory file with nothing on the shelf to copy.
Highlights from the episode:
- Strategies for communicating novel technology with regulatory agencies and ensuring robust science-driven submissions (02:34)
- What differentiates the analytical characterization of PLVs compared to standard recombinant proteins or antibodies (04:03)
- The development plan and regulatory pathway towards clinical and commercial approval for their lead leptin therapy (05:35)
- The evolving role of advanced techniques—such as cryo-EM—in supporting regulatory filings and product understanding (06:56)
- Jitendra Kumar's career journey: from agricultural research in India to protein science and neurodegeneration, and how these experiences inform current PLV technology development (09:00)
- Challenges of early diagnostics and product development in neurodegenerative diseases (14:29)
- Decision-making differences and focus in academic versus industry biotech research (15:32)
- Practical advice on the importance of honest technology assessment, building networks, and understanding both strengths and weaknesses (16:16)
Smart insight: A persistent challenge for groundbreaking delivery systems is the lack of established regulatory playbooks. Jitendra Kumar laid out a science-first approach: let data do the talking, supported by rigorous GLP toxicology studies and transparent communication with agencies. Regulatory bodies like Health Canada are receptive to innovation, provided that sponsors demonstrate safety, efficacy, and scientific rationale for any deviation from standard criteria.
If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:
- Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
- Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef
- Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Jitendra Kumar:
- LinkedIn: www.linkedin.com/in/jkumar2
- Email: [email protected]
- Website: www.entospharma.com
Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
281: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 1
Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up …
Notes de l’épisode
Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second constraint, since they tend to accumulate in the liver, which narrows the diseases they can reach. What if the particle never entered that way at all?
Jitendra Kumar, Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, works on a platform that fuses directly with the cell membrane and releases its cargo straight into the cytosol. He came to nanoparticle design the long way, through fifteen years of structural biology on the prion protein in Frankfurt and Edmonton, which is why he thinks about particle size, packaging and diffusion the way he does.
Key topics discussed:
- Jitendra’s career background in structural biology and journey to Entos Pharmaceuticals (03:18)
- The scientific motivation and challenges of working with prion proteins and breaking down complex diseases (04:55)
- Genetic medicine approaches: gain-of-function vs. loss-of-function, and the role of siRNA, ASOs, and gene delivery (06:27)
- The FAST protein platform: origins, function, and advantages for drug delivery (07:56)
- Manufacturing differences compared to LNPs, including the introduction of recombinant membrane protein production and related CMC complexity (09:55)
- Scale-up and production challenges for membrane proteins, and strategies for clinical supply (11:21)
- Clinical development progress: Phase 1/2 studies with the platform, especially for COVID vaccine delivery (12:23)
- Focus areas for the technology, including selective lung delivery and leptin therapy for lipodystrophy (13:12)
- Lessons for small biotech companies in phase 1/2 manufacturing strategy, technology transfer, and the value of an experienced network (14:31)
- Balancing process robustness with speed in new biotech ventures (16:02)
- The importance of identifying “pause steps” and must-have vs. nice-to-have features in early manufacturing processes (17:15)
Smart insight: Jitendra’s takeaway for startups: for early phases, find a partner who genuinely understands your tech and can move at your pace rather than defaulting to a big CDMO, treat your network as infrastructure, and build the ability to run production in-house. The one thing that's never up for negotiation is process robustness. The real question isn't robustness vs. speed, but how many checkpoints and safe pause points you build in so you can have both.
If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:
- Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
- Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef
- Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville
Connect with Jitendra Kumar:
- LinkedIn: www.linkedin.com/in/jkumar2
- Email: [email protected]
- Website: www.entospharma.com
Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher - Part 2
For decades, drug development has been saddled with costly manufacturing, stringent biosafety requirements, and the limits of conventional carriers. But a new approach—born from cell-derived nanovesicles—could …
Notes de l’épisode
For decades, drug development has been saddled with costly manufacturing, stringent biosafety requirements, and the limits of conventional carriers. But a new approach—born from cell-derived nanovesicles—could democratize access to advanced therapies and open entirely new doors for oral, topical, and even global vaccine delivery.
This week, David Brühlmann welcomes Christopher Locher, CEO and Co-founder of Versatope Therapeutics. Christopher has shaped the translation of novel vesicle technology from idea to clinical pipeline, navigating both the science and the unstructured realm of first-in-class GMP manufacturing.
Topics discussed:
- Tackling GMP manufacturing challenges and analytics development from scratch (00:34)
- Deciding what to outsource vs. insource as a small biotech, and the value of a robust tech transfer process (02:25)
- Perspectives on partnering with CDMOs versus managing manufacturing and analytics in-house (02:40)
- Geographic expansion goals and considerations for delivering low-cost biologics in underserved markets (04:26)
- Differentiators of Versatope’s platform—endotoxin-free processes and non-pathogenic strains (05:05)
- Key advice on critical quality attributes and early regulatory planning for Phase 1 readiness (06:19)
- Lessons learned as a biotech founder—getting support, leveraging networks, and planning cost-effectively (07:57)
- Understanding end users, leveraging I-Corps™, and customer discovery in early product development (09:04)
- The science and promise of engineered nanovesicles: delivery routes, biological origins, and research applications (10:12)
- Business models for platform out-licensing and potential for co-development partnerships (12:58)
- Practical takeaways for scientists: setting "good enough" standards and focusing on lean, regulatory-aligned development (13:28)
Smart insight: Christopher is honest about his blind spots, learning on the fly from CMC consultants, and the practical importance of “good enough” regulatory solutions delivers sharp advice for anyone charting the long road from discovery to human trials. Think monoclonal analytics, batch consistency, and the art of prioritization, all from someone who’s made it work with a small team and limited resources
If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.
- Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
- Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
- Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal
Connect with Christopher Locher:
Website: www.versatope.com
LinkedIn: www.linkedin.com/in/christopher-locher-biotech279: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher - Part 1
What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?While much of the industry focuses on refining existing delivery systems, Christopher …
Notes de l’épisode
What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?
While much of the industry focuses on refining existing delivery systems, Christopher Locher is charting a new course—one inspired by nature’s own couriers. Imagine a future where oral vaccines and modular, on-demand manufacturing aren’t just possibilities, but standard practice.
Christopher Locher, CEO and Co-founder of Versatope Therapeutics, brings decades of experience in drug discovery from Vertex Pharmaceuticals, Opsona Therapeutics, and Maxigen. In this episode, he shares his journey from high school science classrooms to the helm of a company pioneering recombinant extracellular transport vesicles—nanovesicles that promise to transform vaccine delivery and immunomodulation.
Topics discussed:
- How basic scientific curiosity and the inspiration from teachers sparked Christopher's career in biotechnology (03:39)
- The unmet needs in vaccine development for infectious and parasitic diseases, especially in regions below the equator (04:17)
- Engineering nanovesicles as immunomodulators and drug delivery vehicles, using microbial bioreactors for production (06:38)
- Co-producing proteins and vesicles in a single process, and the flexibility of the platform (08:28)
- Key benefits of Versatope's platform, such as cost efficiency, stability, and commercial scalability compared to mammalian exosomes (09:53)
- Prospects for multi-specific vaccines and the future direction for scalable bioprocessing (11:47)
- Adapting manufacturing processes and overcoming logistical challenges—from COVID-related shutdowns to supply chain bottlenecks (12:21)
- Strategies for navigating evolving regulatory requirements with agencies like the FDA, and experience with fast IND allowance (14:53)
- Analytical and characterization challenges of complex nanovesicle-based products versus simpler platforms like antibodies (17:30)
- The vision for decentralized or local vaccine manufacturing, especially in resource-limited settings (19:12)
Smart insight: Christopher Locher highlighted that the FDA allowed their IND submission for a universal influenza vaccine in less than a month after review—and notably, with no hold clinical questions—when it was submitted just before the Christmas holidays and allowed on January 19th, 2025. This rapid regulatory turn-around was made possible by a strong regulatory team and collaborative CDMO efforts, showcasing how innovative platforms and well-prepared submissions can accelerate early-stage clinical development in biotech.
If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.
- Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
- Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer
- Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
- Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal
Connect with Christopher Locher:
Website: www.versatope.com
LinkedIn: www.linkedin.com/in/christopher-locher-biotech278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano - Part 2
How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano …
Notes de l’épisode
How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, pushes back on the premise: the process you run today is already governed by a mathematical model, fitted once at small scale during process characterization and then left untouched for years, even as the process shifts.
Part 1 separated digital models from digital shadows and digital twins, and made the case for starting with the decision rather than the data. Part 2 goes into the plant: what regulators actually require, what the numbers looked like on a real biologics process, and where a team should start on Monday morning.
Topics covered:
- Core differences—and surprising similarities—between modeling in development versus manufacturing (02:35)
- Regulatory requirements: credibility assessments, model risk, and validation steps for digital twins (05:07)
- Real-world example: How deploying an end-to-end process model led to 35% yield increase for Takeda, and considerations for ROI in manufacturing (08:34)
- Advice for startup leaders on when to invest in modeling and how to scale efforts case-by-case (11:42)
- Steps for scientists new to modeling: identifying bottlenecks, starting simple, and proving value offline before scaling up (12:26)
- The importance of understanding basic statistics before relying on AI-generated models (15:22)
- A stepwise summary for deploying digital modeling effectively in biotech (16:01)
Smart insight: The digital twin is the last step, not the first. Identify the bottleneck, build the simplest model that supports the decision, and concatenate it end to end so you can see how a parameter moves final drug substance quality rather than one unit operation's output. Prove the value offline. Only then connect interfaces, because that is where the cost and the validation burden live. Teams that lead with the twin arrive at the C-level with a proof of concept and no evidence. Teams that lead with the offline model arrive with a number.
Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.
- Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
- Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
- Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
- Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
Connect with Ignasi Bofarull-Manzano:
LinkedIn: www.linkedin.com/in/ignasi-bofarull
Körber Pharma website: www.koerber-pharma.com
277: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano - Part 1
Most bioprocess teams believe a digital twin demands vast datasets and sophisticated models. Ignasi Bofarull-Manzano argues both assumptions are wrong, and that the data already sitting in your Excel files …
Notes de l’épisode
Most bioprocess teams believe a digital twin demands vast datasets and sophisticated models. Ignasi Bofarull-Manzano argues both assumptions are wrong, and that the data already sitting in your Excel files, historians and ELNs is probably enough to start.
Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, breaks down what a digital twin actually is, where modeling pays back fastest across the product lifecycle, and how to tell a real business case from an expensive proof of concept.
In this episode:
- Misconceptions about data requirements for digital twins—why quality and context of data matter more than sheer quantity (02:40)
- Ignasi’s journey from curiosity in biology to a career in data science, modeling, and digital twins (04:31)
- Clear distinctions between digital models, digital shadows, and digital twins, explained with real-world analogies (06:42)
- How to approach digital development when faced with legacy data silos and scattered analytics (09:56)
- The importance of starting with a focused business need instead of chasing trends or buzzwords (12:28)
- Insights into where modeling truly delivers value in the product lifecycle—development versus manufacturing (13:11)
- Strategies for small companies to leverage digitalization and data from the ground up (15:56)
- An accessible overview of physics-informed AI, physical AI, and hybrid modeling—and their application in bioprocessing (18:15)
- The comparative advantages of physics-informed AI versus hybrid models in different bioprocessing contexts (24:45)
Smart insight: Do not start with the model. Start with the bottleneck. Identify the business need first, then the decision the model must support, then the minimum data required for that context of use. Build the model offline, concatenate it end to end across unit operations rather than optimizing one in isolation, and prove the value before connecting a single interface. Teams that skip this sequence end up building models because models sound impressive, and those projects get expensive before they get useful.
Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.
- Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
- Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
- Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
- Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
Connect with Ignasi Bofarull-Manzano:
LinkedIn: www.linkedin.com/in/ignasi-bofarull
Körber Pharma website: www.koerber-pharma.com
Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here
276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet - Part 2
How do you turn a lab-born regenerative medical device into a solution that surgeons actually want to use and investors want to back? The path from academic innovation to clinical adoption is full of practical …
Notes de l’épisode
How do you turn a lab-born regenerative medical device into a solution that surgeons actually want to use and investors want to back? The path from academic innovation to clinical adoption is full of practical hurdles and strategic pivots, where compelling science alone isn’t enough.
David Brühlmann welcomes back Eva-Maria Balet, whose journey spans tissue engineering research at EPFL to leading Regenosca through first-in-human trials, fundraising, and an executive MBA completed while running the company. This conversation covers the practical realities behind that journey, from quality control to clinical setbacks to investor pitches.
Topics discussed:
- Defining TissueSpan’s regulatory path and quality control as a medical device (02:49)
- The significance of first-in-human studies and what early clinical experience reveals (04:11)
- Selecting an initial clinical indication and opportunities for technology expansion (05:50)
- Realistic assessment of where soft tissue repair technologies apply—and where they do not (07:18)
- The stepwise progression from in vitro to animal models in product development (08:18)
- Navigating setbacks, including the impact of Covid-19 on clinical trials, and the value of adaptability (10:36)
- Bridging science and business in biotech fundraising and communication (12:15)
- Key takeaways from pursuing an executive MBA alongside building a biotech company (13:42)
- The importance of collaboration, mindset, and meaningful networks in driving biotech innovation (15:19)
Smart insight: The transition from scientist to founder brought its own learning curve. Eva-Maria pursued an executive MBA while running Regenosca, and points to financial and business vocabulary as the skill she'd have built earlier if she could. For a technical founder or CMC lead, the lesson isn't to become a business generalist, it's that the moment you're translating a manufacturing process or clinical dataset into an investor pitch, fluency in the language of accounting, market strategy, and cost structure becomes as load-bearing as the science itself.
This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.
- Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
- Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic
- Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
- Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
Connect with Eva-Maria Balet:
LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737
Regenosca website: www.regenosca.com275: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet - Part 1
Imagine a wound too large for the body to close on its own. That's the problem Eva-Maria Balet set out to solve, not with living cells, but with a structural bridge that lets the body's own healing …
Notes de l’épisode
Imagine a wound too large for the body to close on its own. That's the problem Eva-Maria Balet set out to solve, not with living cells, but with a structural bridge that lets the body's own healing mechanisms do the rest.
In this episode, David Brühlmann welcomes Eva-Maria Balet, Co-Founder & CEO of Regenosca. Trained at EPFL, Eva-Maria brought her fascination with cellular "factories" from academia straight into entrepreneurship. Rather than chasing elegant science for its own sake, she built her company around a single principle: start with a real clinical need and build backward, collaborating with clinicians from day one so every experiment serves a patient.
Highlights & Topics:
- Why starting with clinical needs—not just scientific excitement—creates meaningful real-world impact in life sciences (02:38)
- How Eva-Maria’s fascination with biotechnology guided her from cell factories to developing scaffolds for tissue repair (03:51)
- The unmet challenges in current soft tissue repair treatments and where new solutions are needed (05:51)
- What makes Regenosca’s fully-engineered collagen implant, TissueSpan, different from existing meshes and biological materials (07:09)
- The biological mechanisms behind tissue regeneration using a temporary collagen scaffold (08:28)
- Translating lab-scale research into a robust, scalable, and regulatory-compliant production process (10:34)
- The practical realities and hurdles of navigating the medical device vs. biologic regulatory pathways (11:59)
- Advice on building regulatory expertise into your founding team or leveraging consultants effectively (13:31)
- The importance of interdisciplinary teams and trust when forming biotech startups (14:36)
Smart insight: Eva-Maria put it plainly: what works in the lab has to work reliably every single time you produce it for a patient. That shift, from proving a concept to controlling a process, from raw materials through in-process controls to final product testing, is the same discipline any CMC scientist recognizes: science alone doesn't get a product to patients. Reproducibility does.
This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.
- Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
- Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic
- Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
- Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
Connect with Eva-Maria Balet:
LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737
Regenosca website: www.regenosca.com
Voici les 40 derniers épisodes sur 305. Les épisodes plus anciens se trouvent dans le flux du podcast.
Podcasts similaires
Plus de podcasts : Sciences
C’est votre podcast ?
Confirmez-le avec une entrée dans votre flux : vous recevez ici un code, vous l’ajoutez comme podcast:txt dans le canal de votre flux, et nous le vérifions. Votre podcast apparaît ensuite comme « vérifié » sur SoundNode.